A cohort of 76 patients with previous chemotherapy for Hodgdevelopment of MDS and AML after intensive chemotherapy kin's disease and non-Hodgkin lymphomas received high-dose and ASCT, the importance of antecedent radiotherapy and carmustine, etoposide, cytosine-arabinoside and melphalan chemotherapy as well as of the transplantation procedure (BEAM) followed by autologous stem cell transplantation have been in focus. [4] [5] [6][7][8] [9] From our institution we have previously (ASCT) and was followed for relapse and development of leu- followed by ASCT for malignant lymphomas, in most cases During the period January 1991 to July 1995 a total of 27 t-MDS and t-AML rather than the BEAM and ASCT regimen, which however may accelerate the evolution of the disease.
Introduction
Fifty-four patients received stem cells isolated from the bone marrow without priming or purging whereas 22 received stem In a search for more curative regimens in patients suffering cells isolated from peripheral blood after priming with cyclofrom leukemias, malignant lymphomas and solid tumors, phosphamide and G-CSF mobilization, but likewise without high-dose chemotherapy followed by allogeneic or autolopurging. Most of the patients had been treated repeatedly for gous stem cell transplantation (ASCT) is used increasingly.
relapsing lymphoma before transplantation. Patient characterThis has raised the question whether these new therapies may istics including histology, age, sex and the number of cycles result in an increased risk of secondary malignancies. So far, with alkylating agents mainly MOPP (mechlorethamin, vincritwo different patterns of secondary tumor have been observed stin, procarbazin and prednisone) and CHOP (cyclowith a highly increased risk. The first pattern includes lymphophosphamide, doxorubicin, vincristin and prednisone), with proliferative disorders, primarily non-Hodgkin lymphomas or without radiotherapy, administered before BEAM and and various types of skin cancer, characteristically observed ASCT, are shown in Table 1 . Likewise, the current status of after chemotherapy and allogeneic bone marrow transplanthe primary lymphoma, and the observation period after tation. [1] [2] [3] The second pattern comprises MDS and AML BEAM and ASCT are shown in the Table. characteristically observed after chemotherapy and ASCT. [3] [4] [5] [6] [7] [8] [9] All 76 patients have been followed till death or termination For the development of the transplantation-related lymphoof this study (July 1996) . Laboratory investigations performed proliferative disorders, immunosuppression, immune stimuroutinely in all surviving patients at least every fourth month lation and EB-virus infection seem to play a major role, [10] [11] [12] included Hb, leukocyte count, differential count and platelet while for the development of skin cancer the role of infection count. In patients developing refractory cytopenia or leukowith human papilloma virus has been discussed. 13 For the cytosis, a bone marrow examination was performed including cytology and cytogenetic examination. In addition, there was routine cytologic and cytogenetic examination of the bone Finally, the risk of t-MDS and t-AML observed in the present study was compared to previously observed risks in seven were compared with the immunological characteristics as observed by fluorescence-activated cell sorting analysis of cohorts of patients treated for various malignant diseases with conventional chemotherapy at our department and subjected Ficoll-Isopaque-isolated mononuclear cells using a panel of monoclonal antibodies. Overt t-AML was subclassified to a similar follow-up for leukemic complications. [14] [15] [16] Because four out of six cases of leukemic complications were according to the French-American-British (FAB) nomenclature. 17 observed in patients treated for Hodgkin's disease, we specifically compared the cumulative risk of t-MDS and t-AML Cytogenetic investigations were performed on bone marrow aspirates from the iliac crest using the GTL-banding technique following high-dose BEAM and ASCT with the observed risk in patients with Hodgkin's disease grouped according to the after a 1-4-day culture. The results were expressed in accordance with the International System for Human Cytogenetic number of cycles of chemotherapy administered with an alkylating agent.
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Nomenclature (ISCN 1995). 18 The six new patients with leukemic complications observed in the present study represent cases Nos 156-161 in our consecutive series of patients with t-MDS and t-AML studied cytogenetically. 19 Their clinical and Results cytogenetic data are presented in Table 2 in the same way as previously.
Six out of 76 patients treated for malignant lymphomas with high-dose BEAM followed by ASCT developed t-MDS or tThe cumulative risk of t-MDS or t-AML was estimated by the Kaplan-Meier method 20 and expressed as percentage ± AML. The most important clinical data and the cytogenetic characteristics of these six patients are shown in Table 2 . Four s.e. For comparison, the risk was calculated separately from the time of start of the first chemotherapy with an alkylating of them were previously treated for Hodgkin's disease, two for non-Hodgkin lymphomas. Five of them had previously agent for lymphoma and from the time of subsequent highdose BEAM and ASCT. Differences in the risk of leukemia received two to three chemotherapy regimens for relapse of their lymphomas, whereas only one patient had entered between groups of patients were estimated by the log rank test, 21 and relative risks of a leukemic complication and its BEAM and ASCT therapy during her first remission of a lymphoblastic non-Hodgkin lymphoma (case No. 160). Only one 95% CI by comparing the observed two cases of overt AML with the expected number of de novo AML based on the sexleukemic patient (case No. 161) with relapse of a non-Hodgkin lymphoma had received chemotherapy of shorter duration specific and age-adjusted incidence of AML in the general Table 2 Characteristics of six patients with t-MDS or t-AML following BEAM and ASCT for malignant lymphomas Therapy-related leukemia after BEAM and autologous stem cell transplantation J Pedersen-Bjergaard et al 1657 after BEAM plus ASCT. Three had previous radiotherapy. In four of the leukemic patients their primary lymphoma was in complete remission, whereas two suffered from relapse simultaneously with the development of leukemic complications. The latent periods from start of the different types of primary therapy for lymphoma till the development to t-MDS or t-AML are shown in Table 2 . From the time of first administered chemotherapy, the latent period varied between 16 and 74 months, from the time of high-dose BEAM and autologous stem cell transplantation the latent period till the leukemic complication varied between 4 and 43 months. Four out of the six patients presented with t-MDS, so far without subsequent transformation to AML, whereas two patients presented with overt t-AML.
All six leukemic patients showed clonal chromosome abnormalities of the bone marrow as described in Table 2 . Three patients presented one single chromosome abnormality whereas three patients presented multiple aberrations. The primary abnormalities characteristic of t-MDS and t-AML included a deletion of part of the long arm of a chromosome No. 7 in two cases, and loss of a whole chromosome No. 5 in one patient. Furthermore, a balanced t(9;21)(p13;q22), and a gain of a whole X chromosome were observed in one case each. Secondary abnormalities characteristic of t-MDS and t-AML were observed in all three patients with a complex karyotype and included a translocation to the short arm of a chromosome No. 3 from an unknown partner and deletions of the short arm of chromosome No. 12 and the long arm of chromosome No. 11, observed in one case each.
The RR of overt AML if evaluated from the time of the start of primary chemotherapy for lymphoma was 357 (95% CI, 43-1290), as two cases of overt AML were observed, whereas only 0.0056 cases of de novo AML were expected among the 76 patients observed for a total of 3842 months. If only the period following high-dose BEAM + ASCT is considered, the RR was 800 (95% CI, 97-2890). As shown in Figure 1 , the cumulative actuarial risk of a leukemic complication was 17.3% (s.e. 8.5) 74 months from start of the primary chemotherapy for lymphoma, and 24.5% (s.e. 12.9) 43 months from the time of BEAM and ASCT therapy.
The risk of t-MDS and t-AML observed in the present study is compared directly in Figure 1 with the cumulative risks of MDS and AML as observed previously in our patients treated conventionally for Hodgkin's disease with up to six cycles, seven to 12 cycles and more than 12 cycles of MOPP or The risk of t-MDS and t-AML in the present study is in Figure 2 indicates ± s.e.).
compared to the risk we observed previously in seven different cohorts of patients treated conventionally with chemotherapy Discussion and subjected to the same follow-up procedure as in the present study. As seen in the Figure, high-dose BEAM plus
The present study demonstrates a very high risk of t-MDS and ASCT seems not to increase the risk of leukemic complications t-AML in intensively treated patients with Hodgkin's disease substantially above the level observed after conventional and non-Hodgkin lymphomas following high-dose BEAM and chemotherapy.
ASCT, even if taking the large s.e. into consideration. If comTwo patients, one with MDS and one with overt AML, are pared to other studies of similarly treated patients [4] [5] [6] [7] [8] (Table 3) , still alive and under observation, whereas four patients are the cumulative risk we observed was comparable to the results dead. Intensive antileukemic chemotherapy was attempted in from Minnesota 5 and Dana-Farber. 7 The high risk observed in one of the surviving patients (No. 160, Table 2 ) who is still in all three studies could relate to several factors. These include complete remission, whereas the other (No. 158) suffers from a heavy load of previous chemotherapy with alkylating agents a persistent myelodysplasia.
before high-dose chemotherapy and ASCT, the high-dose emphasizes that antecedent chemotherapy is the most important risk factor for subsequent development of t-MDS and t-AML. Also the short latent period from BEAM and ASCT to the development of t-MDS and t-AML, observed in four of our six cases of t-MDS and t-AML, supports that the previously administered chemotherapy is responsible at least for these early cases.
That the high-dose BEAM-ASCT regimen has a low leukemogenic potential is further stressed by the facts that t-MDS and t-AML are rare in patients treated with this or similar regimens for lymphomas in first complete remission, and in patients treated with similar high-dose chemotherapy and allogeneic bone marrow transplantation. [1] [2] [3] The low leukemogenic potential of BEAM and ASCT may be analogous to the well established low leukemogenic potential of current highvoltage radiotherapy. In this case it is assumed that most hematopoietic precursor cells are killed within the field of irradiation, leaving only a small number for possible malignant transformation. Based on our present knowledge it is therefore reasonable to suggest that most leukemias observed after high-dose BEAM and ASCT originate from a pre-transplant damage of the stored hematopoietic precursor cells used for transplantation.
A very brief latent period from high-dose chemotherapy and ASCT to the development of t-MDS and t-AML has previously been observed by others, for instance in three out of nine cases in the study from Minnesota 5 and in three out of 20 cases in the Dana-Farber series. 7 Our results confirm these observations. The very brief latent period suggests that highdose BEAM and ASCT in some cases might accelerate the development of leukemic complications, perhaps due to a high proliferative activity of the hematopoietic precursor cells with self-renewal during repopulation of the bone marrow.
The cytogenetic characteristics of our six cases of t-MDS and t-AML are similar to findings in previously reported cases after high-dose chemotherapy and ASCT, [4] [5] [6] [7] and similar to findings in therapy-related leukemia more generally. 19, 23, 24 The deletions of 7q and the loss of a chromosome No. 5 observed in three patients are among the most common primary aberrations in t-MDS and t-AML. Deletions of 11q and 12p, like abnormalities of chromosome No. 3, are characteristic secondary abnormalities. 19 The t(9;21)(p13;q22) observed in patient No. 159, presenting as overt AML of FAB subtype M1, is an interesting new variant translocation to chromosome band 21q22. In addition to other drugs this patient had previously received 7 months of therapy with doxorubicin for inhibitors such as doxorubicin. 25, 26 Recently we observed another similar variant translocation: t(1;21)(p36;q23), likewise after therapy with a DNA topoisomerase II inhibitor. 19 At chemotherapy and ASCT regimen in itself and a close clinical follow-up with extended use of cytogenetic investigation, perpresent we are examining the cells from case No. 159 with t(9;21) for rearrangement of the AML1 gene at chromosome formed in most surviving patients. If compared to our previous experience in seven cohorts of patients treated intensively band 21q22. The results of the present and previous studies 4-8 all suggest with conventional chemotherapy for lymphomas and solid tumors and subjected to a similar follow-up (Figure 2) , the risk that high-dose chemotherapy followed by ASCT in patients with Hodgkin's disease and non-Hodgkin lymphomas of poor in the present study is not extreme. In patients with for instance, Hodgkin's disease treated with more than six cycles prognosis should be explored as front-line therapy rather than as rescue for relapse, in an attempt to achieve a higher chance of combination chemotherapy including an alkylating agent and procarbazine, we previously observed a similar cumulatof primary cure and to avoid an unnecessarily high risk of t-MDS and t-AML. Our present knowledge does not indicate ive risk of t-MDS and t-AML 22 (Figure 1 ). This indicates that therapy with BEAM and ASCT does not increase the risk of that such an approach should result in a specific high risk of leukemic complications. All future patients with intensively leukemic complications, at least to any major degree, and
